Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 490

1.

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.

Jones SE, Cantrell J, Vukelja S, Pippen J, O'Shaughnessy J, Blum JL, Brooks R, Hartung NL, Negron AG, Richards DA, Rivera R, Holmes FA, Chittoor S, Whittaker TL, Bordelon JH, Ketchel SJ, Davis JC, Ilegbodu D, Kochis J, Asmar L.

J Clin Oncol. 2007 Oct 20;25(30):4765-71.

PMID:
17947724
[PubMed - indexed for MEDLINE]
2.

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.

Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E.

J Clin Oncol. 2006 Feb 20;24(6):910-7.

PMID:
16484701
[PubMed - indexed for MEDLINE]
3.

Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).

Takei H, Ohsumi S, Shimozuma K, Takehara M, Suemasu K, Ohashi Y, Hozumi Y.

Breast Cancer Res Treat. 2012 May;133(1):227-36. doi: 10.1007/s10549-011-1943-y. Epub 2012 Jan 11.

PMID:
22234519
[PubMed - indexed for MEDLINE]
4.

Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.

Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A.

J Clin Oncol. 2004 Nov 1;22(21):4261-71.

PMID:
15514369
[PubMed - indexed for MEDLINE]
5.

Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.

Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A; ATAC Trialistsa9 Group.

Breast Cancer Res Treat. 2006 Dec;100(3):273-84. Epub 2006 Jun 21.

PMID:
16944295
[PubMed - indexed for MEDLINE]
6.

Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study.

Pandya KJ, Raubertas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ, Pierce HI, Dragalin V, Morrow GR.

Ann Intern Med. 2000 May 16;132(10):788-93.

PMID:
10819701
[PubMed - indexed for MEDLINE]
7.

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE Jr, Costantino JP, Wolmark N.

J Clin Oncol. 2008 Apr 20;26(12):1965-71. doi: 10.1200/JCO.2007.14.0228. Epub 2008 Mar 10.

PMID:
18332472
[PubMed - indexed for MEDLINE]
8.

Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.

Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB.

Breast J. 2006 Mar-Apr;12(2):114-22.

PMID:
16509835
[PubMed - indexed for MEDLINE]
9.
10.

The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.

Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, Lappas H, Gogas H.

Breast Cancer Res Treat. 2005 Sep;93(1):61-6.

PMID:
16184460
[PubMed - indexed for MEDLINE]
11.

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.

Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ; IES Steering Committee.

Lancet Oncol. 2012 Apr;13(4):420-32. doi: 10.1016/S1470-2045(11)70328-X. Epub 2012 Jan 20.

PMID:
22265698
[PubMed - indexed for MEDLINE]
12.

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.

Hadji P, Ziller M, Kieback DG, Dornoff W, Tessen HW, Menschik T, Kuck J, Melchert F, Hasenburg A.

Ann Oncol. 2009 Jul;20(7):1203-9. doi: 10.1093/annonc/mdn762. Epub 2009 Feb 13.

PMID:
19218306
[PubMed - indexed for MEDLINE]
Free Article
13.

Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.

Morales L, Neven P, Timmerman D, Christiaens MR, Vergote I, Van Limbergen E, Carbonez A, Van Huffel S, Ameye L, Paridaens R.

Anticancer Drugs. 2004 Sep;15(8):753-60.

PMID:
15494636
[PubMed - indexed for MEDLINE]
14.

The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial.

Kroiss R, Fentiman IS, Helmond FA, Rymer J, Foidart JM, Bundred N, Mol-Arts M, Kubista E.

BJOG. 2005 Feb;112(2):228-33.

PMID:
15663589
[PubMed - indexed for MEDLINE]
15.

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC; Intergroup Exemestane Study group.

Lancet Oncol. 2007 Feb;8(2):119-27.

PMID:
17267326
[PubMed - indexed for MEDLINE]
16.

Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.

Love RR, Hutson PR, Havighurst TC, Cleary JF.

Clin Cancer Res. 2005 Feb 15;11(4):1500-3.

PMID:
15746052
[PubMed - indexed for MEDLINE]
Free Article
17.

Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial.

Sismondi P, Kimmig R, Kubista E, Biglia N, Egberts J, Mulder R, Planellas J, Moggio G, Mol-Arts M, Kenemans P.

Maturitas. 2011 Dec;70(4):365-72. doi: 10.1016/j.maturitas.2011.09.003. Epub 2011 Oct 26.

PMID:
22030384
[PubMed - indexed for MEDLINE]
18.

Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.

Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, Van Dam FS, Schagen SB.

Acta Oncol. 2009;48(1):76-85. doi: 10.1080/02841860802314738.

PMID:
18777410
[PubMed - indexed for MEDLINE]
19.

Menopausal symptoms in older women and the effects of treatment with hormone therapy.

Barnabei VM, Grady D, Stovall DW, Cauley JA, Lin F, Stuenkel CA, Stefanick ML, Pickar JH.

Obstet Gynecol. 2002 Dec;100(6):1209-18. Erratum in: Obstet Gynecol. 2003 Mar;101(3):619.

PMID:
12468165
[PubMed - indexed for MEDLINE]
20.

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Lancet Oncol. 2008 Sep;9(9):840-9. doi: 10.1016/S1470-2045(08)70204-3. Epub 2008 Aug 19.

PMID:
18718815
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk